Treace Medical Concepts financials
$4.62+3.13%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $212.7M | $209.4M | $187.1M | $141.8M | $94.4M |
| Gross profit | $169.8M | $168.3M | $151.9M | $116.3M | $77.5M |
| Gross margin | 79.8% | 80.4% | 81.2% | 82.0% | 82.1% |
| Operating income | -$54.2M | -$55.7M | -$51.4M | -$34.8M | -$16.5M |
| Net income | -$59.0M | -$55.7M | -$49.5M | -$42.8M | -$20.7M |
| Net margin | −27.7% | −26.6% | −26.5% | −30.2% | −22.0% |
| Diluted EPS | $-0.93 | $-0.90 | $-0.81 | $-0.77 | $-0.43 |
| EBITDA | -$43.5M | -$47.3M | -$46.1M | -$34.8M | -$15.8M |
| Operating cash flow | -$16.0M | -$37.2M | -$34.6M | -$30.6M | -$17.2M |
| Free cash flow | -$29.5M | -$48.8M | -$46.0M | -$45.5M | -$19.9M |
| Diluted shares | 63.3M | 62.1M | 60.9M | 55.3M | 48.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $10.7M | $11.3M | $13.0M | $19.5M | $105.8M |
| Short-term investments | $37.7M | $64.3M | $110.2M | $61.8M | $0.00 |
| Total debt | $55.6M | $53.3M | $53.0M | $52.7M | $29.4M |
| Total assets | $190.6M | $217.1M | $251.9M | $159.0M | $140.8M |
| Total liabilities | $103.2M | $104.2M | $114.0M | $98.5M | $47.7M |
| Shareholders' equity | $87.3M | $112.9M | $137.9M | $60.5M | $93.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology